NCT06648785

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Vermont Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single arm, non-randomized feasibility study with tolerability and toxicity evaluation as primary endpoints which seeks to determine if a modified administration schedule of capecitabine with oxaliplatin will result in less toxicity than standard FOLFOX or CAPOX regimens.

Conditions

• GI Cancers

Interventions

Type	Name	Description
DRUG	oxaliplatin	85 mg/m2 oxaliplatin
DRUG	Fluoropyrimidine	oral fluoropyrimidine 1000mg/m2

Timeline

• Start date: 2024-10-21
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2024-10-18
• Last updated: 2026-02-05

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study